Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis

Frequency, stability and clinicopathologic correlations

Sean J Pittock, M. Reindl, S. Achenbach, T. Berger, W. Bruck, F. Konig, Y. Morales, H. Lassmann, S. Bryant, S. B. Moore, B Mark Keegan, Claudia F Lucchinetti

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Controversy exists regarding the pathogenic or predictive role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with multiple sclerosis (MS). Four immunopathological patterns (IP) have been recognized in early active MS lesions, suggesting heterogeneous pathogenic mechanisms. Whether MOG antibodies contribute to this pathological heterogeneity and potentially serve as biomarkers to identify specific pathological patterns is unknown. Here we report the frequencies of antibodies to human recombinant MOG (identified by Western blot and enzyme-linked immunoabsorbent assay (ELISA)) in patients with pathologically proven demyelinating disease, and investigate whether antibody status is associated with clinical course, HLA-DR2-genotype, IP or treatment response to plasmapheresis. The biopsy cohort consisted of 72 patients: 12 pattern I, 43 pattern II and 17 pattern III. No association was found between MOG antibody status and conversion to clinically definite MS, DR-2 status, IP or response to plasmapheresis. There was poor agreement between Western blot and ELISA (kappa =0.07 for MOG IgM). Fluctuations in antibody seropositivity were seen for 3/4 patients tested serially by Western blot. This study does not support a pathologic pattern-specific role for MOG-antibodies. Variable MOG-antibody status on serial measurements, coupled with the lack of Western blot and ELISA correlations, raises concern regarding the use of MOG-antibody as an MS biomarker and underscores the need for methodological consensus.

Original languageEnglish (US)
Pages (from-to)7-16
Number of pages10
JournalMultiple Sclerosis
Volume13
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Myelin-Oligodendrocyte Glycoprotein
Multiple Sclerosis
Antibodies
Western Blotting
Plasmapheresis
Enzymes
Biomarkers
HLA-DR2 Antigen
Demyelinating Diseases
Immunoglobulin M
Genotype
Biopsy

Keywords

  • ELISA
  • Immunological patterns
  • MOG antibodies
  • Multiple sclerosis
  • Western blot

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis : Frequency, stability and clinicopathologic correlations. / Pittock, Sean J; Reindl, M.; Achenbach, S.; Berger, T.; Bruck, W.; Konig, F.; Morales, Y.; Lassmann, H.; Bryant, S.; Moore, S. B.; Keegan, B Mark; Lucchinetti, Claudia F.

In: Multiple Sclerosis, Vol. 13, No. 1, 01.2007, p. 7-16.

Research output: Contribution to journalArticle

Pittock, Sean J ; Reindl, M. ; Achenbach, S. ; Berger, T. ; Bruck, W. ; Konig, F. ; Morales, Y. ; Lassmann, H. ; Bryant, S. ; Moore, S. B. ; Keegan, B Mark ; Lucchinetti, Claudia F. / Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis : Frequency, stability and clinicopathologic correlations. In: Multiple Sclerosis. 2007 ; Vol. 13, No. 1. pp. 7-16.
@article{e27aaa57bc564ff79278eff7fa78db51,
title = "Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: Frequency, stability and clinicopathologic correlations",
abstract = "Controversy exists regarding the pathogenic or predictive role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with multiple sclerosis (MS). Four immunopathological patterns (IP) have been recognized in early active MS lesions, suggesting heterogeneous pathogenic mechanisms. Whether MOG antibodies contribute to this pathological heterogeneity and potentially serve as biomarkers to identify specific pathological patterns is unknown. Here we report the frequencies of antibodies to human recombinant MOG (identified by Western blot and enzyme-linked immunoabsorbent assay (ELISA)) in patients with pathologically proven demyelinating disease, and investigate whether antibody status is associated with clinical course, HLA-DR2-genotype, IP or treatment response to plasmapheresis. The biopsy cohort consisted of 72 patients: 12 pattern I, 43 pattern II and 17 pattern III. No association was found between MOG antibody status and conversion to clinically definite MS, DR-2 status, IP or response to plasmapheresis. There was poor agreement between Western blot and ELISA (kappa =0.07 for MOG IgM). Fluctuations in antibody seropositivity were seen for 3/4 patients tested serially by Western blot. This study does not support a pathologic pattern-specific role for MOG-antibodies. Variable MOG-antibody status on serial measurements, coupled with the lack of Western blot and ELISA correlations, raises concern regarding the use of MOG-antibody as an MS biomarker and underscores the need for methodological consensus.",
keywords = "ELISA, Immunological patterns, MOG antibodies, Multiple sclerosis, Western blot",
author = "Pittock, {Sean J} and M. Reindl and S. Achenbach and T. Berger and W. Bruck and F. Konig and Y. Morales and H. Lassmann and S. Bryant and Moore, {S. B.} and Keegan, {B Mark} and Lucchinetti, {Claudia F}",
year = "2007",
month = "1",
doi = "10.1177/1352458506072189",
language = "English (US)",
volume = "13",
pages = "7--16",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis

T2 - Frequency, stability and clinicopathologic correlations

AU - Pittock, Sean J

AU - Reindl, M.

AU - Achenbach, S.

AU - Berger, T.

AU - Bruck, W.

AU - Konig, F.

AU - Morales, Y.

AU - Lassmann, H.

AU - Bryant, S.

AU - Moore, S. B.

AU - Keegan, B Mark

AU - Lucchinetti, Claudia F

PY - 2007/1

Y1 - 2007/1

N2 - Controversy exists regarding the pathogenic or predictive role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with multiple sclerosis (MS). Four immunopathological patterns (IP) have been recognized in early active MS lesions, suggesting heterogeneous pathogenic mechanisms. Whether MOG antibodies contribute to this pathological heterogeneity and potentially serve as biomarkers to identify specific pathological patterns is unknown. Here we report the frequencies of antibodies to human recombinant MOG (identified by Western blot and enzyme-linked immunoabsorbent assay (ELISA)) in patients with pathologically proven demyelinating disease, and investigate whether antibody status is associated with clinical course, HLA-DR2-genotype, IP or treatment response to plasmapheresis. The biopsy cohort consisted of 72 patients: 12 pattern I, 43 pattern II and 17 pattern III. No association was found between MOG antibody status and conversion to clinically definite MS, DR-2 status, IP or response to plasmapheresis. There was poor agreement between Western blot and ELISA (kappa =0.07 for MOG IgM). Fluctuations in antibody seropositivity were seen for 3/4 patients tested serially by Western blot. This study does not support a pathologic pattern-specific role for MOG-antibodies. Variable MOG-antibody status on serial measurements, coupled with the lack of Western blot and ELISA correlations, raises concern regarding the use of MOG-antibody as an MS biomarker and underscores the need for methodological consensus.

AB - Controversy exists regarding the pathogenic or predictive role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with multiple sclerosis (MS). Four immunopathological patterns (IP) have been recognized in early active MS lesions, suggesting heterogeneous pathogenic mechanisms. Whether MOG antibodies contribute to this pathological heterogeneity and potentially serve as biomarkers to identify specific pathological patterns is unknown. Here we report the frequencies of antibodies to human recombinant MOG (identified by Western blot and enzyme-linked immunoabsorbent assay (ELISA)) in patients with pathologically proven demyelinating disease, and investigate whether antibody status is associated with clinical course, HLA-DR2-genotype, IP or treatment response to plasmapheresis. The biopsy cohort consisted of 72 patients: 12 pattern I, 43 pattern II and 17 pattern III. No association was found between MOG antibody status and conversion to clinically definite MS, DR-2 status, IP or response to plasmapheresis. There was poor agreement between Western blot and ELISA (kappa =0.07 for MOG IgM). Fluctuations in antibody seropositivity were seen for 3/4 patients tested serially by Western blot. This study does not support a pathologic pattern-specific role for MOG-antibodies. Variable MOG-antibody status on serial measurements, coupled with the lack of Western blot and ELISA correlations, raises concern regarding the use of MOG-antibody as an MS biomarker and underscores the need for methodological consensus.

KW - ELISA

KW - Immunological patterns

KW - MOG antibodies

KW - Multiple sclerosis

KW - Western blot

UR - http://www.scopus.com/inward/record.url?scp=33846520073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846520073&partnerID=8YFLogxK

U2 - 10.1177/1352458506072189

DO - 10.1177/1352458506072189

M3 - Article

VL - 13

SP - 7

EP - 16

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 1

ER -